Company intelligence / Profile preview

Integro Theranostics

St. Louis, Missouri, United Statesintegrotheranostics.com ↗

Ownership: Private
Development stage: Other

Overview

Integro Theranostics has initiated a Phase 1b/2 study to evaluate the safety, efficacy, and pharmacokinetics of LS301, a novel fluorescent imaging agent administered intravenously to women undergoing partial mastectomy or sentinel lymph node biopsy for DCIS or early-stage invasive breast cancer. The primary objective is safety; secondary objectives include efficacy based on real-time fluorescence-guided tumor visualization during surgery. No published top-line results as of May 2025.

Therapeutic areas: Oncology
Modalities: Fluorescent imaging agents (small molecule-based)
Industry: Biotech

Drug pipeline

1 asset

ls301

Partnerships

OmniScience – partnership to integrate AI-powered image analysis and data management into oncology clinical trials using OmniScience’s Vivo platform.

Beyond the preview

Go deeper on Integro Theranostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integro Theranostics.